Drug intelligence / Profile preview

2Br-NDIA

Development stage: Preclinical
Lead developer: Sun Yat-sen University
Modality: Small Molecules

Overview

2Br-NDIA is a novel polycyclic conjugated small molecule that functions as a photothermal agent for cancer therapy. It is characterized by its ability to convert light energy into heat, which subsequently activates the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel. This activation facilitates a significant influx of calcium ions into the cell, specifically targeting the mitochondria to induce calcium overload. This process disrupts intracellular calcium homeostasis and overcomes tumor resistance mechanisms. 2Br-NDIA has been studied primarily in the context of hepatocellular carcinoma, often delivered via multifunctional nanoparticles (such as the CNQ system) to enhance therapeutic precision and efficacy.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on 2Br-NDIA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2Br-NDIA.

Explore the full profile